According to data compiled by the Knowledge Portal on Innovation and Access to Medicines, as of March 2021, more than 6 billion Euros of R&D have been invested in Covid-19 vaccines.

The biggest share comes from the United States, which accounted for about 2 billion Euros or 31% of the total funding, followed by Germany with 1.3 billion Euros or 21%, and the United Kingdom with nearly 433 million Euros or 7%.

While EU institutions accounted for only 5% of the total funding with almost 283 million Euros, the combination of EU funding with the national funding from several EU Member States accounted for 28% and more than 1.7 billion Euros. It is also important to highlight that CEPI (Coalition for Epidemic Preparedness Innovations) accounted alone for 18% of the total R&D funding.

Despite the fact the United States are the biggest funder, the EU countries and UK combined are the biggest recipients, accounting for 44% of the funding, receiving more than 2.7 billion Euros.

The figures do not include pharmaceutical industry’s own investments.

According to the Knowledge Portal on Innovation and Access to Medicines, information on R&D investments is collected from publicly available sources, including news, reports, academic articles, and data repositories (Policy Cures Research COVID-19 R&D tracker, ACT-Accelerator Tracker). Some data limitations are also explained in the website.

More information.